Several treatment routes exist for cancer, a rare condition or serious complex illness. You need to understand what each means for this patient.
| What to assess | Stanford Medicine / Cleveland Clinic | Evidence OS · Commissioned scope |
|---|
| Service focus | Stanford lists USD975 for a written opinion. Cleveland lists US options at USD1690/1990 and international at USD4500, with China among excluded countries. Confirm fees and eligibility with the institution. | EOS proposes traceable comparison of the evidence, patient fit and differences across several routes, with patient/clinician versions and an update baseline. |
|---|
| When to choose | Another qualified clinician’s assessment of a diagnosis and treatment plan, delivered through an institution. | Pilot baseline: one patient, one decision stage, up to 5 key questions and 3 candidate routes, 100 authorized record pages and 30 priority sources; one scoping discussion, one evidence discussion and one clarification round. Quote and delivery window follow confirmation of records, specialty and reviewers. |
|---|
- What the fee pays for
- Assessment CNY 3,000; stage CNY 29,800–98,000. Clients decide whether to proceed after assessment. Credit the assessment against the same-scope full commission. New clinical stages, questions or record batches require an agreed change.
- Value beyond this task
- Agreed professional review record, unresolved issues and an update baseline. Illustrative total CNY 48,000 includes the CNY 3,000 assessment. This is not a completed client case, overseas specialist fee or treatment charge. Acceptance depends on the agreed work and traceable deliverables, not treatment changes, cost savings or survival improvement.
- How to assess value
- Check responses to the agreed questions, traceable sources, record gaps and differing opinions. For overseas routes, also check incremental services and third-party fees. Clinical outcomes are not consulting acceptance criteria.
Personal evidence consulting is not oncology treatment, pathological diagnosis or prescribing. Relevant specialist qualifications and review responsibilities must be confirmed before accepting a cancer or rare-condition commission. The patient and treating team make the treatment decision.
